9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED) [clinicaltrials:NCT00143182]

Bio2RDF identifier

NCT00143182

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00143182

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00143182

actual enrollment [clinicaltrials_vocabulary:actual-enrollment]

504

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT00143182 arm group c4ca4238a0b923820dcc509a6f75849b [clinicaltrials_resource:NCT00143182/arm-group/c4ca4238a0b923820dcc509a6f75849b]

NCT00143182 arm group c81e728d9d4c2f636f067f89cc14862c [clinicaltrials_resource:NCT00143182/arm-group/c81e728d9d4c2f636f067f89cc14862c]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:d942c8692d257084abf3ac87279faff6

brief summary [clinicaltrials_vocabulary:brief-summary]

Bipolar disorder is cha ...... y for an additional 40 weeks.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

9 Week Extension Study of Asen ...... t of Mania (P07007)(COMPLETED)

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Maintenance of the effect (Asenapine comparable to olanzapine in terms of the reduction of symptoms achieved in the short term (ie. 3 week studies [A7501004 or A7501005]) as measured on the Young Mania Rating Scale The YMRS is administered at weeks 1, 3, 6 and 9 or endpoint. [clinicaltrials_resource:8abae86bcc0539dfa905df4ccf24dc85]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Maintenance of the effect (Asenapine comparable to olanzapine in terms of the reduction of symptoms achieved in the short term (ie. 3 week studies [A7501004 or A7501005]) as measured on the Young Mania Rating Scale The YMRS is administered at weeks 1, 3, 6 and 9 or endpoint. [clinicaltrials_resource:397dfe403afb70ee7a5a9fd45a0b37a9]

Maintenance of the effect (Asenapine comparable to olanzapine in terms of the reduction of symptoms achieved in the short term (ie. 3 week studies [A7501004 or A7501005]) as measured on the Young Mania Rating Scale The YMRS is administered at weeks 1, 3, 6 and 9 or endpoint. [clinicaltrials_resource:4825f1dbe2151f56a066f05fa2b3c4cf]

Maintenance of the effect (Asenapine comparable to olanzapine in terms of the reduction of symptoms achieved in the short term (ie. 3 week studies [A7501004 or A7501005]) as measured on the Young Mania Rating Scale The YMRS is administered at weeks 1, 3, 6 and 9 or endpoint. [clinicaltrials_resource:6fe73660a0b1789634684e1e18b31f61]

Maintenance of the effect (Asenapine comparable to olanzapine in terms of the reduction of symptoms achieved in the short term (ie. 3 week studies [A7501004 or A7501005]) as measured on the Young Mania Rating Scale The YMRS is administered at weeks 1, 3, 6 and 9 or endpoint. [clinicaltrials_resource:7b8c3a0befe528de7857ea4eff347922]

Maintenance of the effect (Asenapine comparable to olanzapine in terms of the reduction of symptoms achieved in the short term (ie. 3 week studies [A7501004 or A7501005]) as measured on the Young Mania Rating Scale The YMRS is administered at weeks 1, 3, 6 and 9 or endpoint. [clinicaltrials_resource:7ea7ead24e063356dd506acf85a7731d]

Maintenance of the effect (Asenapine comparable to olanzapine in terms of the reduction of symptoms achieved in the short term (ie. 3 week studies [A7501004 or A7501005]) as measured on the Young Mania Rating Scale The YMRS is administered at weeks 1, 3, 6 and 9 or endpoint. [clinicaltrials_resource:a19a2adbfb0ec23b058e9a651678583b]

Maintenance of the effect (Asenapine comparable to olanzapine in terms of the reduction of symptoms achieved in the short term (ie. 3 week studies [A7501004 or A7501005]) as measured on the Young Mania Rating Scale The YMRS is administered at weeks 1, 3, 6 and 9 or endpoint. [clinicaltrials_resource:defaf2a931f450fa9f4c8ace72d7533d]

collaborator [clinicaltrials_vocabulary:collaborator]

Merck Sharp & Dohme Corp. [clinicaltrials_resource:bd932dcb36d27f98f1bb6129a9c0d723]

completion date [clinicaltrials_vocabulary:completion-date]

2006-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00143182 [clinicaltrials_resource:3fb39896856826f179e2d571db9f56f3]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2005-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Asenapine [clinicaltrials_resource:6d2de7f98fb07468ad59cc14b460f63e]

Olanzapine [clinicaltrials_resource:94b5f02c9b6a1ec6b1142374350122c5]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Olanzapine [clinicaltrials_resource:394044b3109fa091d34a85a6ff71e1dd]

Asenapine [clinicaltrials_resource:3e380e274490b075ffc1291070fe33e4]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

Yes

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-05-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Merck Sharp & Dohme Corp. [clinicaltrials_resource:bd932dcb36d27f98f1bb6129a9c0d723]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00143182

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

2

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Double-Blind, 9-Week Extensi ...... 501006 (Secondary Title: ARES)

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

P07007

http://www.w3.org/2001/XMLSchema#string

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:be4cea82cb21bbda79c939a4d720315b]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2006-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

secondary id [clinicaltrials_vocabulary:secondary-id]

A7501006

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

Merck Sharp & Dohme Corp. [clinicaltrials_resource:bd932dcb36d27f98f1bb6129a9c0d723]

start date [clinicaltrials_vocabulary:start-date]

2005-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00143182 study design [clinicaltrials_resource:a8c6d0beee62a8ad418bd235d2d346f7]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00143182

verification date [clinicaltrials_vocabulary:verification-date]

2015-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00143182

http://www.w3.org/2001/XMLSchema#string

title

9 Week Extension Study of Asen ...... t of Mania (P07007)(COMPLETED)

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

9 Week Extension Study of Asen ...... ) [clinicaltrials:NCT00143182]

@en